ArticleAnnals of surgical oncology2026
Multiplication of Alpha-Fetoprotein and Protein Induced by Vitamin K Absence-II is Associated with Prognosis After Pulmonary Metastasectomy in Hepatocellular Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purposeThe role of pulmonary metastasectomy for hepatocellular carcinoma (HCC) has declined with the advent of effective systemic therapies, but selected patients may still benefit from surgical treatment. The AP factor, defined as alpha-fetoprotein (AFP) × protein induced by vitamin K absence-II (PIVKA-II), has been proposed as a prognostic biomarker for HCC. This study evaluated the association between the AP factor and outcomes in patients undergoing pulmonary metastasectomy for recurrent HCC after hepatectomy.
methodsWe retrospectively analyzed patients who underwent resection of pulmonary metastases after hepatectomy for HCC between 1990 and 2025. Patients with uncontrolled intrahepatic disease, non-curative resection, extra-pulmonary metastases, or missing tumor marker data were excluded. Overall survival (OS) and recurrence-free survival (RFS) after lung resection were analyzed using the log-rank test. Multivariate analysis was performed using Cox proportional hazards models.
resultsForty-three patients underwent pulmonary metastasectomy. The median follow-up period was 3.6 years. The 5-year OS and RFS rates were 46.4% and 8.0%, respectively, with a median OS of 51.8 months. An AP factor ≥100,000 was associated with markedly poor survival (5-year OS 0.0% vs. 51.1%, p<0.0001). Multivariate analysis identified an AP factor ≥100,000 as an independent predictor of OS (p=0.010), whereas AFP ≥500 ng/mL independently predicted RFS (p=0.036).
conclusionsThe AP factor is associated with overall survival in patients undergoing pulmonary metastasectomy for recurrent HCC. Patients with an AP factor ≥100,000 have extremely poor outcomes after surgery, suggesting that careful patient selection for surgical resection is warranted.
Indexed as
Identifiers
42189439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.